Neurocrine Biosciences Inc (NBIX) stock
NBIXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 20/3012% below fair value
$165.31−2.09 (-1.25%)
Close on Nov 16, 2026Market cap $16.80BP/E 24.5Yield –
Neurocrine Biosciences r&d expenses
Research and development expenses are spending on new products and technology.
Neurocrine Biosciences's R&D Expenses for the twelve months ending Sep 30, 2026 was $1.23B, up 30.7% year over year. For fiscal 2025 it was $1.02B, up 38.9% from the year before. Over ten years it grew 36.1% a year on average. The highest annual figure on record is $1.02B in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.02B | +38.9% |
| FY2024 | Dec 31, 2024 | $731.10M | +29.4% |
| FY2023 | Dec 31, 2023 | $565.00M | +21.8% |
| FY2022 | Dec 31, 2022 | $463.80M | +41.4% |
| FY2021 | Dec 31, 2021 | $328.10M | +19.3% |
| FY2020 | Dec 31, 2020 | $275.00M | +71.3% |
| FY2018 | Dec 31, 2018 | $160.52M | +31.8% |
| FY2017 | Dec 31, 2017 | $121.83M | +29.2% |
| FY2016 | Dec 31, 2016 | $94.29M | +15.7% |
| FY2015 | Dec 31, 2015 | $81.49M | +75.5% |
| FY2014 | Dec 31, 2014 | $46.43M | +18.3% |
| FY2013 | Dec 31, 2013 | $39.25M | +5.6% |
| FY2012 | Dec 31, 2012 | $37.16M | +20.1% |
| FY2011 | Dec 31, 2011 | $30.95M | -0.6% |
| FY2010 | Dec 31, 2010 | $31.15M | -7.6% |
| FY2009 | Dec 31, 2009 | $33.72M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $351.80M | +40.7% |
| Q2 FY2026 | Jun 30, 2026 | $326.70M | +33.7% |
| Q1 FY2026 | Mar 31, 2026 | $296.20M | +12.5% |
| Q4 FY2025 | Dec 31, 2025 | $258.20M | +39.1% |
| Q3 FY2025 | Sep 30, 2025 | $250.00M | +28.2% |
| Q2 FY2025 | Jun 30, 2025 | $244.30M | +27.8% |
| Q1 FY2025 | Mar 31, 2025 | $263.20M | +65.1% |
| Q4 FY2024 | Dec 31, 2024 | $185.60M | +35.0% |
| Q3 FY2024 | Sep 30, 2024 | $195.00M | +37.1% |
| Q2 FY2024 | Jun 30, 2024 | $191.10M | +31.1% |
| Q1 FY2024 | Mar 31, 2024 | $159.40M | +14.3% |
| Q4 FY2023 | Dec 31, 2023 | $137.50M | +16.5% |
| Q3 FY2023 | Sep 30, 2023 | $142.20M | +32.0% |
| Q2 FY2023 | Jun 30, 2023 | $145.80M | +7.3% |
| Q1 FY2023 | Mar 31, 2023 | $139.50M | +36.5% |
| Q4 FY2022 | Dec 31, 2022 | $118.00M | +35.0% |
| Q3 FY2022 | Sep 30, 2022 | $107.70M | +16.2% |
| Q2 FY2022 | Jun 30, 2022 | $135.90M | +81.7% |
| Q1 FY2022 | Mar 31, 2022 | $102.20M | +39.6% |
| Q4 FY2021 | Dec 31, 2021 | $87.40M | +31.0% |
| Q3 FY2021 | Sep 30, 2021 | $92.70M | +34.2% |
| Q2 FY2021 | Jun 30, 2021 | $74.80M | -7.5% |
| Q1 FY2021 | Mar 31, 2021 | $73.20M | +25.6% |
| Q4 FY2020 | Dec 31, 2020 | $66.70M | +47.2% |
| Q3 FY2020 | Sep 30, 2020 | $69.10M | +12.0% |
| Q2 FY2020 | Jun 30, 2020 | $80.90M | +114.9% |
| Q1 FY2020 | Mar 31, 2020 | $58.30M | +49.1% |
| Q3 FY2019 | Sep 30, 2019 | $45.30M | +27.7% |
| Q2 FY2019 | Jun 30, 2019 | $61.70M | +66.8% |
| Q1 FY2019 | Mar 31, 2019 | $37.65M | -23.1% |
| Q4 FY2018 | Dec 31, 2018 | $39.11M | +52.7% |
| Q3 FY2018 | Sep 30, 2018 | $35.48M | +58.0% |
| Q2 FY2018 | Jun 30, 2018 | $36.99M | +69.1% |
| Q1 FY2018 | Mar 31, 2018 | $48.95M | -5.7% |
| Q4 FY2017 | Dec 31, 2017 | $25.61M | +13.4% |
| Q3 FY2017 | Sep 30, 2017 | $22.46M | – |
| Q2 FY2017 | Jun 30, 2017 | $21.87M | – |
| Q1 FY2017 | Mar 31, 2017 | $51.88M | – |
| Q4 FY2016 | Dec 31, 2016 | $22.58M | – |
See a number that looks wrong?